Literature DB >> 8888468

Willingness to pay for child survival: results of a national survey in Central African Republic.

M Weaver1, R Ndamobissi, R Kornfield, C Blewane, A Sathe, M Chapko, N Bendje, E Nguembi, J Senwara-Defiobona.   

Abstract

Many policy-makers and health economists are interested in designing and implementing user fee/quality improvement programs in public facilities in Sub-Saharan Africa on a national scale. This research addresses two design issues for a national program: (1) to what extent would user fees finance the costs of quality improvements, and (2) whether a uniform program could be implemented throughout the country or the user fees should differ between urban and rural areas or across health regions. A national survey was conducted to determine the population's willingness and ability to pay for seven quality improvements: (1) facility maintenance, (2) supervision of personnel, and drugs to treat (3) diarrheal diseases, (4) acute respiratory infections (ARI), (5) malaria, (6) intestinal parasites, and (7) sexually transmitted diseases (STDs). Willingness to pay for quality improvements was measured by contingent valuation techniques in which subjects were asked about expenditures for care at government facilities under a hypothetical user fee/quality improvement program. Ability to pay was measured by monthly expenditures for health care as a percentage of monthly household consumption. The majority of the population was willing to pay the cost of the quality improvements, which ranged from U.S. $0.40 to U.S. $4.00. Estimates of the percentage of the population that was willing to pay the cost of the quality improvements ranged from 81% for facility maintenance (an improvement with the lowest cost) to 64% for drugs to treat ARI (the improvement with the highest cost). The median willingness to pay ranged from U.S. $7.98 for drugs to treat malaria to U.S. $16.61 for drugs to treat diarrheal diseases. Willingness to pay was greater in rural areas than in urban areas. It was also greater in Health Region I than in Health Regions IV and V. The population was able to pay the estimated cost of all seven quality improvements. Median monthly health care expenditures per episode of illness was 2.6% of median monthly household consumption. In comparison, the estimated cost of the quality improvements ranged from 0.2 to 2.4% median monthly household consumption. The national user fee/quality improvement program has good prospects for financing the quality improvements because the majority of the population is willing to pay the estimated costs of the quality improvements and more than half of the population is willing to pay substantially more than the costs. It also appears that the user fees should differ between urban and rural areas and across some health regions.

Entities:  

Mesh:

Year:  1996        PMID: 8888468     DOI: 10.1016/0277-9536(96)00015-9

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  4 in total

Review 1.  Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules.

Authors:  Samuel D Shillcutt; Damian G Walker; Catherine A Goodman; Anne J Mills
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 2.  A systematic review of stated preference studies reporting public preferences for healthcare priority setting.

Authors:  Jennifer A Whitty; Emily Lancsar; Kylie Rixon; Xanthe Golenko; Julie Ratcliffe
Journal:  Patient       Date:  2014       Impact factor: 3.883

3.  Increasing coverage of insecticide-treated nets in rural Nigeria: implications of consumer knowledge, preferences and expenditures for malaria prevention.

Authors:  Obinna Onwujekwe; Benjamin Uzochukwu; Nkoli Ezumah; Elvis Shu
Journal:  Malar J       Date:  2005-07-18       Impact factor: 2.979

4.  Willingness-to-pay for a rapid malaria diagnostic test and artemisinin-based combination therapy from private drug shops in Mukono District, Uganda.

Authors:  Kristian Schultz Hansen; Debora Pedrazzoli; Anthony Mbonye; Sian Clarke; Bonnie Cundill; Pascal Magnussen; Shunmay Yeung
Journal:  Health Policy Plan       Date:  2012-05-15       Impact factor: 3.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.